Medicare Enrolled

Dr. Donald Richards, MD

Medical Oncology · Tyler, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Consulting-driven
501 SAUNDERS AVE STE 200, Tyler, TX 75702
9035799800
In practice since 2006 (19 years)
NPI: 1659313559 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Richards from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Richards? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Richards

Dr. Donald Richards is a medical oncology specialist in Tyler, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Richards performed 116,825 Medicare services across 4,648 unique beneficiaries.

Between the years covered by Open Payments, Dr. Richards received a total of $40,917 from 40 pharmaceutical and/or device companies across 133 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Richards is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 6% volume in TX $40,917 industry payments

Medicare Practice Summary

Medicare Utilization ↗
116,825
Medicare services
Top 6% in TX for medical oncology
4,648
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,149 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron infusion (Feraheme) 16,830 $0 $5
Pembrolizumab injection (Keytruda) 16,200 $43 $136
Nivolumab injection (Opdivo) 13,080 $24 $76
Oxaliplatin chemotherapy injection 10,700 $0 $33
Paclitaxel chemotherapy injection 10,218 $0 $8
Iron sucrose injection (Venofer) 7,300 $0 $2
Contrast dye for imaging (iodine-based) 7,259 $0 $3
Daratumumab injection (Darzalex) 5,940 $38 $128
Darbepoetin injection (Aranesp) for anemia 5,040 $2 $20
Dexamethasone injection (steroid) 2,971 $0 $1
Immune globulin infusion (Octagam) 2,550 $34 $233
Anti-nausea injection (fosaprepitant) 2,250 $0 $5
Denosumab injection (Prolia/Xgeva) 1,800 $18 $66
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg 1,500 $23 $155
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg 986 $24 $181
Blood draw (venipuncture) 979 $8 $20
Injection, granisetron hydrochloride, 100 mcg 960 $0 $24
Comprehensive metabolic blood panel 857 $10 $64
Complete blood count (CBC) with differential 844 $8 $36
Injection of additional new drug or substance into vein 667 $12 $108
Anti-nausea injection (Aloxi/palonosetron) 630 $1 $114
Injection, leucovorin calcium, per 50 mg 539 $3 $25
Injection, fluorouracil, 500 mg 494 $2 $13
Office visit, established patient (20-29 min) 459 $63 $250
Administration of chemotherapy into vein, 1 hour or less 456 $98 $707
Injection, carboplatin, 50 mg 373 $2 $300
Injection, zoledronic acid, 1 mg 346 $7 $431
Office visit, established patient (30-39 min) 273 $95 $368
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg 264 $96 $1,348
Injection, potassium chloride, per 2 meq 255 $0 $1
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg 225 $3 $373
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 209 $22 $157
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 182 $46 $313
Cyclophosphamide, 100 mg 180 $17 $203
Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session 168 $272 $2,762
Injection, cisplatin, powder or solution, 10 mg 157 $2 $94
Injection, diphenhydramine hcl, up to 50 mg 156 $1 $7
Administration of additional new drug or substance into vein, 1 hour or less 139 $48 $344
Immunoglobulin level test 129 $9 $56
Administration of chemotherapy into vein, each additional hour 124 $21 $161
Injection, magnesium sulfate, per 500 mg 104 $1 $6
Drug injection, under skin or into muscle 102 $10 $96
Iron level test 99 $6 $27
Iron binding capacity test 99 $9 $35
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg 99 $354 $1,722
Ferritin level test (iron stores) 97 $13 $60
Carcinoembryonic antigen (cea) protein level 96 $19 $99
Magnesium level test 94 $7 $29
Reticulated (young) platelet measurement 83 $35 $143
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle 78 $55 $211
Ct scan of chest with contrast 75 $48 $821
Unclassified drugs 75 $1 $8
Microscopic examination for white blood cells with manual cell count 73 $4 $22
Complete blood count (CBC), automated 73 $6 $34
Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services 72 $69 $70
Infusion, normal saline solution , 1000 cc 68 $2 $19
Leuprolide acetate (for depot suspension), 7.5 mg 54 $137 $3,675
New patient office visit, complex (60-74 min) 52 $164 $709
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour 49 $16 $100
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l 48 $124 $500
Urea nitrogen level to assess kidney function, quantitative 42 $4 $24
CT scan of abdomen and pelvis with contrast 41 $170 $1,067
Irrigation of implanted venous access drug delivery device 40 $18 $114
PSA test (prostate cancer screening) 38 $18 $94
Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev 33 $178 $700
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion 32 $15 $94
Administration of additional new drug or substance into vein using push technique 29 $42 $289
CT scan of chest, without contrast 28 $43 $686
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle 27 $26 $145
Infusion into a vein for hydration, 31-60 minutes 25 $25 $256
Hospital follow-up visit, moderate complexity 25 $56 $247
Infusion into a vein for hydration, each additional hour 23 $10 $75
Application of on-body injector for under skin injection 22 $14 $96
Ct scan of abdomen and pelvis before and after contrast 19 $196 $1,413
Drawing of blood for a medical problem 19 $62 $264
Infusion, normal saline solution, sterile (500 ml = 1 unit) 19 $1 $19
Ct scan of abdomen and pelvis without contrast 18 $76 $560
Nuclear medicine study from skull base to mid-thigh with ct scan 16 $1,098 $4,802
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries 15 $91 $657
Vitamin B-12 level test 12 $15 $76
New patient office visit (45-59 min) 12 $127 $565
Initial hospital admission, moderate complexity 11 $81 $470
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.1% high complexity
78.4% medium
4.5% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$40,917
Total received (2018-2024)
Avg $5,845/year across 7 years
Top 24% in TX for medical oncology
40
Companies
133
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$25,371 (62.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11,520 (28.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,026 (9.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,369
2023
$3,479
2022
$1,222
2021
$125
2020
$15,566
2019
$12,937
2018
$5,218

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Ipsen Biopharmaceuticals, Inc
$10,340
Seattle Genetics, Inc.
$5,362
Seagen Inc.
$4,431
AstraZeneca Pharmaceuticals LP
$4,066
JAZZ PHARMACEUTICALS INC.
$2,871
F. Hoffmann-La Roche AG
$2,329
Taiho Oncology, Inc.
$2,192
Bayer HealthCare Pharmaceuticals Inc.
$1,645
ARRAY BIOPHARMA INC
$1,591
Incyte Corporation
$1,585
Aadi Bioscience, Inc.
$1,000
Amgen Inc.
$535
Genentech USA, Inc.
$264
ABBVIE INC.
$243
Janssen Biotech, Inc.
$241
PFIZER INC.
$221
Novartis Pharmaceuticals Corporation
$208
Pharmacyclics LLC, An AbbVie Company
$194
Tempus AI, Inc
$147
Exelixis Inc.
$146
E.R. Squibb & Sons, L.L.C.
$130
Puma Biotechnology, Inc.
$125
Ethicon US, LLC
$122
Lilly USA, LLC
$104
SANOFI-AVENTIS U.S. LLC
$100
Myriad Genetic Laboratories, Inc.
$98
Takeda Pharmaceuticals U.S.A., Inc.
$93
Celgene Corporation
$77
Merck Sharp & Dohme Corporation
$73
TESARO, Inc.
$63
Gilead Sciences, Inc.
$51
SOBI, INC
$40
Kite Pharma, Inc.
$40
Astellas Pharma US Inc
$38
Immunocore Limited
$29
Regeneron Healthcare Solutions, Inc.
$29
GENZYME CORPORATION
$28
Stemline Therapeutics Inc.
$27
Pharmacyclics LLC, an AbbVie Company
$20
Iovance Biotherapeutics, Inc.
$17
Top 3 companies account for 49.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · Amtagvi · BOSULIF · BRAFTOVI · CALQUENCE · Cabometyx · DARZALEX · DOPTELET · ELITEK · EPKINLY · ERBITUX · ERLEADA · Erleada · FYARRO · GAZYVA · IMBRUVICA · IMFINZI · IMJUDO · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUTATHERA · LYNPARZA · Lonsurf · MYRISK · NEUWAVE Flex Microwave Ablation System · NINLARO · Nerlynx · Nubeqa · ONIVYDE · OPDIVO · Onivyde · Orserdu · PEMAZYRE · Padcev · Prolia · ROZLYTREK · SARCLISA · SOMATULINE DEPOT · SUTENT · Stivarga · TABRECTA · TAGRISSO · TECENTRIQ · VENCLEXTA · VERZENIO · VONJO · VYXEOS · XALKORI · XT CDX · XTANDI · ZANIDATAMAB · ZEJULA · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (62%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Equivalent to $35 per 100 Medicare services performed
Looking for a medical oncology specialist in Tyler?
Compare medical oncologists in the Tyler area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
4
Per 100K population
1.7
County median income
$71,923
Nearest hospital
UT HEALTH EAST TEXAS TYLER REGIONAL HOSPITAL
3.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Richards is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), with consulting-driven industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Richards experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Richards performed 16,830 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Richards receive payments from pharmaceutical companies?
Yes. Dr. Richards received a total of $40,917 from 40 companies across 133 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Richards's costs compare to other medical oncologists in Tyler?
Dr. Richards's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Richards) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →